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Abstract: Aim: To investigate the effect of normalizing vitamin B12 (B12) levels with oral B12
(methylcobalamin) 1000 µg/day for one year in patients with diabetic neuropathy (DN). Patients and
methods: In this prospective, double-blind, placebo-controlled trial, 90 patients with type 2 diabetes
on metformin for at least four years and both peripheral and autonomic DN were randomized to
an active treatment group (n = 44) receiving B12 and a control group (n = 46) receiving a placebo.
All patients had B12 levels less than 400 pmol/L. Subjects underwent measurements of sural nerve
conduction velocity (SNCV), sural nerve action potential (amplitude) (SNAP), and vibration per-
ception threshold (VPT), and they performed cardiovascular autonomic reflex tests (CARTs: mean
circular resultant (MCR), Valsalva test, postural index, and orthostatic hypotension). Sudomotor
function was assessed with the SUDOSCAN that measures electrochemical skin conductance in
hands and feet (ESCH and ESCF, respectively). We also used the Michigan Neuropathy Screening
Instrument Questionnaire and Examination (MNSIQ and MNSIE, respectively) and questionnaires
to evaluate quality of life (QoL) and level of pain (pain score). Results: B12 levels increased from
232.0 ± 71.8 at baseline to 776.7 ± 242.3 pmol/L at follow-up, p < 0.0001, in the active group but not
in the control group. VPT, MNSIQ, QoL, pain score, SNCV, SNAP, and ESCF significantly improved
in the active group (p < 0.001, p = 0.002, p < 0.0001, p < 0.000, p < 0.0001, p < 0.0001, and p = 0.014,
respectively), whereas CARTS and MNSIE improved but not significantly. MCR, MNSIQ, SNCV,
SNAP, and pain score significantly deteriorated in the control group (p = 0.025, p = 0.017, p = 0.045,
p < 0.0001, and p < 0.0001, respectively). Conclusions: The treatment of patients with DN with
1 mg of oral methylcobalamin for twelve months increased plasma B12 levels and improved all
neurophysiological parameters, sudomotor function, pain score, and QoL, but it did not improve
CARTS and MNSIE.
Keywords: diabetic neuropathy; vitamin B12; SUDOSCAN; metformin; diabetic foot; diabetes
mellitus; autonomic neuropathy; painful neuropathy
1. Introduction
Diabetic neuropathy (DN) is one of the most common microvascular complications
of diabetes. Its most prevalent forms are peripheral (DPN), autonomic (DAN, with the
most commonly diagnosed form being cardiovascular autonomic neuropathy (CAN)),
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and painful (PDN). At the time of diagnosis of diabetes, 10–18% of patients present with
nerve damage, but neuropathy has also been shown to occur even in prediabetes [1].
Peripheral/distal symmetric polyneuropathy may develop in up to 50% of patients [2],
can cause sensory symptoms [3], and is associated with foot infections, ulcers, Charcot
arthropathy, fractures, and amputations [2]. The prevalence of CAN is around 7% by the
time of type 2 diabetes (DM2) diagnosis and increases with increasing diabetes duration
by 4.6% to 6% per year [4,5], as well as to up to 65% of patients with longer durations of
diabetes [6]. Though CAN is considered to be an independent predictor of cardiovascular
mortality, it is often underdiagnosed [7]. One third of patients develop PDN [8] with
neuropathic pain and symptoms such as burning, “pins and needles,” painful cold or hot
sensations, “electric shock”-like pain, numbness and dead feeling in the feet and legs, and
contact pain (allodynia) [9–11], and these have a major impact on the quality of life [8,12,13].
Strict glycemic control has been considered to be the cornerstone of the treatment of
DN. However, it has only modest effects on the progression of DN [14], with a reduction
in the progression of CAN [15], but little or no effect in DPN [15–17]. Nonetheless, large
studies [18,19] do not agree on the optimum level of glycemic control for preventing
neurophysiological deterioration. It is of particular note that strict glycemic control needs
to be maintained for three-to-five years to provide any clinical benefit [20].
In addition to any antiglycemic therapy aiming at strict glycemic control, vitamin B12
(B12) has been probably the most commonly used supplement. The first reason is that vita-
min B12 deficiency is quite common in patients with DM2, and the second is that vitamin
B12 deficiency may cause neurological disorders, such as peripheral, autonomic (including
cardiovascular), and painful neuropathy, resembling or accelerating the progression of
DN [1,7]. Importantly, neuropathy from vitamin B12 deficiency can occur in the absence of
the typical hematological characteristics (e.g., megaloblastic anemia and pancytopenia) of
B12 deficiency [6,21]. Notably, it has been suggested that, especially in diabetic patients
aged over 60 years, the cut-off for B12 levels potentially leading to neurological dysfunction
should be shifted from 150 to 400 pmol/L [22].
According to several reports, the prevalence of vitamin B12 deficiency in DM2 may
exceed 50% of patients [23–28]. The American Diabetes Association (ADA) therefore
recommends that in patients with DN on metformin therapy, vitamin B12 levels should
be regularly monitored on an annual basis [24,29]. At least half of patients with DM2 are
older than 60 years, an age group with a prevalence of confirmed vitamin B12 deficiency
varying from 12% to 23% [30]. However, vitamin B12 deficiency in DM2 has been mostly
attributed to the use of metformin. Metformin-associated vitamin B12 deficiency has been
known for over 40 years, and this relationship has been confirmed by several interventional
studies, observational studies, and meta-analyses [21,23–27,30,31]. The strongest evidence
was brought by a 4.3-year randomized clinical trial (RCT) by De Jager et al. [28]. From
these studies, it has become apparent that metformin causes vitamin B12 deficiency in a
dose- and duration of treatment-dependent manner [24], and that although it may occur as
early as only four months after the initiation of metformin, vitamin B12 deficiency appears
usually after at least four-to-five years of metformin use [7]. It has been reported that
metformin reduces vitamin B12 uptake in terminal ileum in about 30% of patients [32].
However, the exact mechanisms by which vitamin B12 inadequacy arises in chronic-treated
patients are not clear yet [6].
Based on the aforementioned data, several trials have tested the effect of vitamin B12
supplementation on DN [33–39]. However, in all of these studies, either vitamin B12 was
given together with other supplements or glycemic control significantly improved during
the follow-up, making it difficult to distinguish the effect of vitamin B12 supplementation
from that of better glycemic control on DN. Consequently, it remains unclear whether DN
improves purely by the normalization of B12 levels in the presence of good glycemic control.
We therefore undertook the present study to investigate the efficacy of normalizing
vitamin B12 levels with 1000 µg of methylcobalamin (C63H91CoN13O14P) daily in DM2
patients with good glycemic control and generalized neuropathy (both DPN and CAN)
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who were vitamin B12-deficient, partly because they had been on metformin treatment for
at least four years.
2. Materials and Methods
2.1. Patients Recruitment
The study was performed at the diabetes clinic of the University General Hospital
in Thessaloniki, Greece, from January 2018 to February 2020. Ninety adult patients were
enrolled (see Supplementary material; Figure S1, Consort Flow Diagram) who fulfilled the
following inclusion criteria. The first inclusion criterion was being adults (>18 years old)
with DM2 and established DN, both peripheral and autonomic (DPN and DAN, respec-
tively). The diagnosis of DN was set when two or more cardiovascular autonomic reflex
tests (CARTs) were abnormal for DAN and when abnormal nerve conduction velocity
levels with abnormal Michigan Neuropathy Screening Instrument Questionnaire (MNSIQ)
and Michigan Neuropathy Screening Instrument Examination (MNSIE) were present for
DPN [4,5,40,41]. The second inclusion criterion was having a good glycemic control (gly-
cated hemoglobin (HbA1c) between 6.5 and 7.5%) that was stable in the last year before
participating in the study. The third inclusion criterion was having metformin treatment
for at least 4 years. The fourth inclusion criterion low vitamin B12 levels according to
suggested normal values for DM2 patients over 60 years old (<400 pmol/L) [22]. Exclusion
criteria were pernicious anemia, alcoholism, gastrectomy, gastric bypass surgery, pancreatic
insufficiency, malabsorption syndromes, chronic giardiasis, acute infection or cardiovas-
cular event in the last 6 months, surgery involving the small intestine, or HIV infection.
Patients with an estimated glomerular filtration rate (e-GFR) <50 mL/min/1.73 m2 based
on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [42,43] or
taking multivitamins or B12 supplements in the last 12 months were also excluded from
the study.
2.2. Randomization and Allocation
Patients were randomized to receive a new oral dispersible tablet of B12 containing
1000 µg of methylcobalamin (B12 fix 1000 mcg; UNI-PHARMA S.A.) or placebo daily for
12 months. The tablets containing B12 and the placebo had a similar appearance and were
packed in similar containers.
The allocation and randomization of participants in the two groups were performed
by a computerized random sequence of numbers. The randomization order and type of
treatment were also concealed from the responsible researcher and statistician. All tests and
measurements were performed by a physician blind to the type of supplement that each
patient received. There were no drop-outs, as all patients completed the study. The study
was registered at clinicaltrials.gov (Identification Number NCT04706377) and approved
by the Scientific Board and Bioethics committee of our University Hospital (Registration
Number 42439). The study was conducted according the principles of Declaration of
Helsinki. All participants signed an informed consent form.
2.3. Antidiabetic and Concomitant Medication
All patients were treated with a combination of metformin and other oral antidiabetic
drugs (dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists,
and sodium glucose transporters 2 (SGLT-2) inhibitors) or with a combination of metformin
with basal insulin analog and other oral antidiabetic drugs (DPP4 or/and SGLT-2). All
patients had been on metformin treatment for at least 4 years. No patient received a
sulfonylurea or was on a basal–bolus insulin regimen. A total of 78.6% of our patients had
hyperlipidemia (total cholesterol >200 mg/dL, high-density lipoprotein (HDL) cholesterol
<40 mg/dL, and low-density lipoprotein (LDL) cholesterol >130 mg/dL), with 74.3% of
the study population receiving statins. Patients had stable glucose control throughout the
study period, and no change was needed in antiglycemic and concomitant medication.
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With the exception of paracetamol, which was occasionally used for 2–3 days, the patients
were not allowed to take any analgesic other medication throughout the study.
2.4. Measurements and Tests
The assessment of sudomotor function was performed with the SUDOSCAN device,
which makes use of a electrochemical reaction between sweat chloride and stainless steel
electrodes. SUDOSCAN measures electrochemical skin conductance (ESC), the ratio be-
tween the current measured and the voltage applied, and expresses it in microsiemens
(µS) [44–46]. Sural nerve conduction velocity and amplitude were measured using “DPN-
check” (Neurometrix Inc., Waltham, MA, USA) [47]. The validation and details of this
device are described elsewhere [47]. The vibration perception threshold was measured
using a Biothesiometer (Ohio, USA) [48]. The diagnosis of DAN was done according
to the Toronto Consensus panel guidelines and CARTs, which are considered the gold
standard [5]. CARTs were performed with the HOKANSON ANS Reader and included R-R
variation during deep breathing (mean circular resultant (MCR)), Valsalva maneuver (Vals),
a 30:15 ratio expressed as a postural index (PI), and blood pressure response to standing
(orthostatic hypotension (OH)) [4,5,41]. Age-specific values were applied [49]. For the
clinical diagnosis of DPN, the MNSIQ and MNSIE scoring algorithm was used (result ≥2
for lower extremity examination, ≥7 for questionnaire, and ≥2.5 for MNSI examination
were considered abnormal) [40,50,51]. The evaluation of quality of life status was assessed
by the Diabetes Quality of Life Brief Clinical Inventory, a brief form of the questionnaire
used in the Diabetes Control and Complications Trial (DCCT) trial [52]. The level of pain
was evaluated with the PAINDetect questionnaire that is used for the identification of
neuropathic components [53]. All measurements were performed according to interna-
tional guidelines regarding patient preparation, i.e., hydration status, physical activity, and
hypoglycemic events in the day before examination [4,5,51].
2.5. Measurement of Vitamin B12
Vitamin B12 was measured with a Cobas e 602 analyzer with electrochemilumines-
cence (ECLIA). Information of the technique can be found elsewhere [54–56]. The results
are given in pmol/L. All other biochemical parameters (blood count, lipids, lipoproteins,
etc.) were measured with the same analyzer.
2.6. Statistical Analysis
Statistical analyses were performed with IBM SPSS v24 [57]. All continuous variables
were normally distributed and are expressed as mean ± standard deviation. Differences
of parameters at baseline between the active and the placebo group were tested using
independent samples two-tailed t-test. Differences in variables between baseline and
follow-up in each group were tested by a paired samples t-test. To compare the mean
difference of the change between two groups, multiple general linear regression (ANCOVA)
was used adjusted for HbA1c and antiglycemic medication. p < 0.05 was considered
statistically significant.
3. Results
There were no significant differences between the active and placebo groups regarding
demographics, anthropometric measurements, laboratory measurements, and neuropathy
test results at baseline, as shown in Tables 1–3. The mean age of the whole patient cohort
was 63 years old, and the mean duration of DM2 was 12.8 years. All patients had taken
metformin for at least four years (active group: 12.9 ± 8.8 years; placebo: 10.1 ± 5.8 years).
No patient was on basal–bolus insulin treatment.
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Table 1. Demographic characteristics and comorbidities of the study population at baseline.
Active Placebo p
Gender (m/w) 22/22 26/20 0.473
Age (years) 64.0 ± 7.8 61.7 ± 8.3 0.248
Height (cm) 168 ± 11.7 169 ± 8.4 0.560
Body Weight (kg) 88.9 ± 17.7 92.3 ± 21.7 0.471
Diabetes Duration (years) 14.0 ± 8.8 11.6 ± 5.9 0.167
Metformin and Other OADs 24 (54.5) 27 (58.7) 0.663
OADs and Basal Insulin 20 (45.5) 19 (41.3) 0.670
Smoking (%) 9 (20.4) 12 (26.1) 0.210
Cardiovascular Disease * 12 (27.3) 15 (32.6) 0.490
Dyslipidemia 33 (75.0) 34 (73.9) 0.849
Hypertension 34 (77.3) 32 (69.6) 0.289
Metformin Therapy 12.9 ± 8.8 10.1 ± 5.8 0.125
Data are given as means ± standard deviation or n (%). OADs: oral antidiabetic drugs; see Section 2.3 * Cardio-
vascular disease was defined as myocardial infraction or stroke or atrial fibrillation or cardiac arrhythmias or
cerebrovascular disease.
Table 2. Laboratory measurements at baseline in both groups.
Active Placebo p
HbA1c (%) 6.79 ± 0.7 6.82 ± 0.7 0.874
HbA1c (mmol/L) 50.7 ± 7.6 51.0 ± 7.9 0.873
Vitamin B12 (pmol/L) * 232.0 ± 71.8 230.9 ± 85.9 0.788
White Blood Count (103/µL) 7.83 ± 1.3 8.13 ± 0.8 0.246
Hemoglobin (g/dL) 13.82 ± 1.4 13.2 ± 1.2 0.228
Mean Corposcular Volume (fL) 88.6 ± 5.4 87.5 ± 5.4 0.392
Platelets (103/µL) 258.5 ± 35.1 247.8 ± 54.2 0.399
Folic acid (ng/mL) 16.4 ± 8.5 25.7 ± 13.6 0.172
Creatinine (mg/dL) 0.94 ± 0.3 0.85 ± 0.2 0.107
Cholesterol (mg/dL) 174.6 ± 43.8 175.5 ± 48.1 0.934
Triglycerides (mg/dL) 161.6 ± 50.1 148.9 ± 51.7 0.327
High Density Lipoprotein (mg/dL) 46.1 ± 3.1 44.8 ± 11.1 0.661
Low Density Lipoprotein (mg/dL) 104.1 ± 47.2 102.6 ± 45.8 0,580
Abbreviations: HbA1c: glycated hemoglobin; * To convert to pg/mL multiply by 1.355. See Appendix A, Table A3
for reference intervals.
Table 3. Indices of cardiovascular autonomic reflex tests (CARTs) and neuropathy tests at baseline.
Active Placebo p
MNSIQ 5.8 ± 2.2 5.9 ± 2.1 0.772
MNSIE 3.6 ± 2.4 3.8 ± 2.28 0.798
DQOL 39.9 ± 10.3 40.2 ± 11.1 0.722
SNAP (µV) 5.2 ± 4.3 5.1 ± 4.2 0.757
SNCV (m/s) 28.2 ± 22.7 34.8 ± 24.6 0.132
VPT (V) 31.5 ± 14.2 26.8 ± 13.7 0.098
MCR 9.2 ± 10.2 16.3 ± 25.0 0.113
Valsalva 1.51 ± 0.21 1.52 ± 0.3 0.633
PI 4.3 ± 5.8 2.9 ± 2.5 0.362
PO (mmHg) 8.3 ± 12.2 7.3 ± 9.5 0.880
Pain score 18.4 ± 9.2 19.3 ± 8.5 0.397
ESCF (µS) 72.8 ± 10.1 72.4 ± 12.3 0.901
ESCH (µS) 69.1 ± 12.5 69.2 ± 10.0 0.684
Abbreviations: MNSIQ: Michigan Neuropathy Screening Instrument Questionnaire; MNSIE: Michigan Neuropa-
thy Screening Instrument Examination; DQoL: Diabetes Quality of Life Questionnaire; SNAP: sural nerve action
potential (amplitude); SNCV: sural sensory nerve conduction velocity; VPT: vibration perception threshold; MCR:
mean circular resultant; PI: postural index; postural hypotension: PO (orthostatic hypotension; Pain: pain score
questionnaire; ESCF: electrochemical skin conductance in feet; ESCH: electrochemical skin conductance in hands.
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Vitamin B12 levels significantly increased in the active group from 232.0 ± 71.8 pmol/L
at baseline to 776.7 ± 242.3 pmol/L at follow-up, but they did not significantly change in
the placebo group (from 230.9 ± 85.9 to 242.8 ± 100.7, p = 0.338).
During the follow-up, the vibration perception threshold (VPT), MNSIQ, quality of
life (QoL), pain score, sural nerve conduction velocity (SNCV), sural nerve action potential
(amplitude) (SNAP), and electrochemical skin conductance in feet (ESCF) significantly
improved in the active group (p < 0.001, p = 0.002, p < 0.0001, p < 0.000, p < 0.0001, p < 0.0001,
and p = 0.014, respectively), whereas the indices of CARTS and MNSIE did not significantly
improve (Table 4). None of the investigated parameters improved in the placebo group, and
it is noteworthy that MCR, MNSIQ, SNCV, SNAP, and pain score significantly deteriorated
(p = 0.025, p = 0.017, p = 0.045, p < 0.0001, and p < 0.0001, respectively—see Table 4). We
found no significant change of blood pressure, serum lipids, and lipoproteins during the
follow-up. Importantly, glycemic control was fairly acceptable at baseline and did not
worsen during the 12 months of the study.
Table 4. Changes in indices from baseline to follow-up in both groups.
Active Placebo
Baseline 12 months pa Baseline 12 months pb pc
HbA1c (%) 6.79 ± 0.7 6.72 ± 0.7 0.257 6.82 ± 0.7 6.73 ± 0.6 0.312 0.876
HbA1c (mmol/L) 50.7 ± 7.6 49.9 ± 7.6 0.257 51.0 ± 7.9 50.02 ± 6.5 0.312 0.876
B12 (pmol/L) 232 ± 71.8 776.7 ± 242.3 <0.001 230.9 ± 85.9 242.8 ± 100.7 0.338 <0.001
MNSIQ 5.8 ± 2.2 5.44 ± 2.1 0.002 5.97 ± 2.1 6.17 ± 2 0.017 <0.001
MNSIE 3.55 ± 2.4 3.59 ± 2.3 0.663 3.8 ± 2.8 3.6 ± 2.1 0.617 0.607
DQOL 39.9 ± 10.3 38.1 ± 9.5 <0.001 40.2 ± 11.1 40.2 ± 11.1 0.931 0.001
SNAP (µV) 5.2 ± 4.3 7.3 ± 4.7 <0.001 5.1 ± 4.2 4.6 ± 4 <0.001 <0.001
SNCV (m/s) 28.2 ± 22.7 30.31 ± 23.2 <0.001 34.8 ± 24.6 32.9 ± 24.2 0.045 <0.001
VPT (V) 31.5 ± 14.2 23.8 ± 13.6 0.001 26.8 ± 13.7 25.8 ± 13.4 0.250 0.007
MCR 9.2 ± 10.2 12.6 ± 20.4 0.409 16.3 ± 25 7.99 ± 11.8 0.025 0.452
Valsalva 1.51 ± 0.21 1.60 ± 0.23 0.983 1.52 ± 0.3 1.59 ± 0.24 0.853 0.761
PI 4.3 ± 6.4 4.5 ± 6.7 0.700 2.9 ± 2.6 3.2 ± 9.4 0.875 0.954
PO (mmHg) 8.3 ± 12.2 5.2 ± 9.7 0.115 7.3 ± 9.5 7.8 ± 9 0.679 0.108
Pain Score 18.4 ± 9.7 17.1 ± 9 <0.001 19.3 ± 8.5 20.9 ± 8.5 <0.001 <0.001
ESCF (µS) 72.8 ± 10.1 74.5 ± 10.1 0.014 72.4 ± 12.3 71.2 ± 11.6 0.142 0.008
ESCH (µS) 69.14 ± 12.5 71.07 ± 12.4 0.260 69.2 ± 10 69.3 ± 7.8 0.636 0.265
a For difference during follow-up in the active group; b for difference during follow-up in the placebo group; c for difference between
groups adjusted for HbA1c and antidiabetic medication. Abbreviations: HbA1c: glycated hemoglobin; MNSIQ: Michigan Neuropathy
Screening Instrument Questionnaire; MNSIE: Michigan Neuropathy Screening Instrument Examination; DQoL: Diabetes Quality of
Life Questionnaire; SNAP: sural nerve action potential (amplitude); SNCV: sural sensory nerve conduction velocity; VPT: vibration
perception threshold; MCR: mean circular resultant; PI: postural index; Postural hypotension: PO (orthostatic hypotension); Pain: pain
score questionnaire; ESCF: electrochemical skin conductance in feet; ESCH: electrochemical skin conductance in hands.
We found a significant difference in the change from baseline to follow-up between
the active and placebo groups in B12 levels (p < 0.001), MNSIQ (p < 0.001), QoL (p = 0.001),
SNAP (p < 0.001), SNCV (p ≤ 0.001), VPT (p = 0.007), pain score (p < 0.001), and ESCF
(p = 0.008). The change of all other indices and biochemical parameters did not significantly
differ between the two groups (Table 4).
Not a single adverse event suspected or possibly related to the new oral dispersible
tablet of B12 was reported.
4. Discussion
DN is a serious complication of DM2, as it can cause devastating symptoms, including
unremitting and unbearable pain, and can have severe and potentially life-threatening
consequences, such as the so-called “diabetic foot” that is associated with ulcers, infections,
Charcot arthropathy, and amputations [41,58–60]. In particular, CAN is a well-known
independent predictor of cardiovascular mortality [7]. Currently, the only established
non-symptomatic treatment of DN is strict glycemic control, which has to be maintained
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for several years and has a rather limited efficacy on DPN [15,16,18]. There is thus an
urgent need for an effective drug therapy that would act either causally or by modifying
the pathophysiology of DN. Among other drugs and supplements (e.g., alpha lipoic acid,
carnitine, folate, and superoxide dismutase), vitamin B12 has perhaps been the most of-
ten used [3,33–36,38,61–64]. This is because vitamin B12 deficiency is commonly found
in patients with DM2 and vitamin B12 deficiency may cause a variety of neurological
disorders resembling or accelerating DN. Accordingly, several trials have investigated
the effect of supplementation of B12 in DN [3,33–36,38,51,61,62,64,65]. Some of them
reported favorable effects [3,33,36], but no one could prove a “pure” effect of B12 sup-
plementation on improvements in peripheral nerve function. The majority of the studies
were performed in DM2 patients with poor glycemic control (HbA1c: 8–10%) [34,36,61]
and reported concurrent decrease of HbA1c levels or/and body weight during follow-
up [34,36,61]. In other studies, combinations of B12 with other supplements or agents,
not solely B12, were given [3,33,34,36,38,51,61,62,64,65]. In addition, there was a great
variation in these studies in terms of the baseline blood levels (150–450 pmol/L), dose
(25–2000 µg), duration (from 12 to 24 weeks), molecular form (cyano-, methyl-, or hydroxo-
cobalamin) [31,35,62,63,66], and mode of administration (orally or parenterally) of B12 [31],
as well as the inclusion criteria of the study participants (without or with established DN,
DPN, or painful DN) [3,33,34,36,38,51,61,62,64,65].
The present randomized controlled trial was conducted with the aim of answering at
least the first of the aforementioned questions, i.e., whether B12 supplementation (alone)
has an effect on DN independent of the glucose control. We therefore included patients
with DM2 who had acceptable glycemic control (HbA1c levels: 6.5–7.5%) at baseline.
In addition, since the good glycemic control had to be stable in the last year prior to
participation in the study, the patients were expected to remain well-controlled during the
follow-up. Indeed, there was no significant change of HbA1c levels during the trial period
in both the active treatment and the placebo groups. Regarding the outcome of the trial,
we found that the sole administration of methylcobalamin in a daily dose of 1000 µg in
DM2 patients for a year exerted a beneficial effect on all indices, except for CARTs and
MNSIE, of peripheral neuropathy, including neurophysiological parameters, sudomotor
function, level of pain, and quality of life. This trial is thus, to our best knowledge, unique
in the literature, not only because it examined the pure effect of B12 on DN in DM2 patients
with good glycemic control but also because participants had all established peripheral
sensorimotor, autonomic, and painful neuropathy.
Whether the levels of B12 at baseline are critical for B12 to exert any effect on DN
(or on some forms of it) is not clear from the literature. It is of particular note that it has
been suggested that (especially those over 60 years old) diabetic patients may exhibit
neurological dysfunction signs even if B12 levels are above what has been considered the
normal level of 150 pmol/L. According to this suggestion, B12 levels of 150–400 pmol/L
should be considered as a “relative” B12 deficiency in people with diabetes [22]. In several
published studies, B12 levels at baseline were not measured or not mentioned [3,35,62],
probably because B12 was given principally for its putative analgesic action. In other
studies, baseline B12 levels were normal [33,34]. These studies generally showed little
effect of B12 on DN, but the results were not uniform [33–35]. The present trial was designed
to include patients with “relative” or absolute B12 deficiency, first because a clear increase
in B12 level was required if its potential independent effect on DN was to be examined
and second because there was a need to study any analgesic and other disease-modifying
effects of B12 (e.g., on indexes of nerve function such as neurophysiological parameters).
To enrich our sample with B12-deficient patients, we only screened those taking metformin
for at least four years, which is the time period believed to be needed for the development
of metformin-associated B12 deficiency [28]. According to the overall favorable effect of
B12 administration on DN shown in our trial, and since almost 95% of the participants
had this “relative” B12 deficiency (Tables 2 and 4), it is reasonable to recommend B12
supplementation in every patient with DN and B12 levels below 400 pmol/L. Of note, at
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these levels, the classic hematological signs of B12 deficiency (megaloblastic anemia or
pancytopenia) are rarely present, which was also the case in our study (Table 2).
Similarly to the baseline levels of B12, there has been no consistency in existing trials
in the literature in terms of the dose, duration, molecular form, and way of administra-
tion of B12 that are most effective on DN. Most trials had a follow-up period of 12–24
weeks [33–36,38,65], and no one exceeded 24 weeks, as was the case in the present trial,
which lasted one year. In these trials, B12 had been administered in a dose varying from
250 to 2000 µg when given orally and from 1000 to 2000 µg when given intramuscu-
larly [35,63,67,68]. For instance, doses of 250 mcg cyanocobalamin for one year [51] and
1500 mg methylcobalamin for four months [33] led to improvements in neurophysiological
parameters and a substantial increase of B12 levels. However, in our previous study, 250
mcg of cyanocobalamin for one year did not result in the normalization of B12 levels [51].
Clearly, the mode of administration also plays a critical role. Traditionally, B12 is given
intramuscularly in order to overcome any intrinsic factor deficiency. However, an oral
tablet would have several advantages, such as patient autonomy, increased patient satisfac-
tion, reduced treatment costs, and fewer risks for patients receiving anti-coagulants [67–69].
Studies investigating this possibility have suggested that oral administration has equal to
intramuscular effects [66–71] ameliorating both biochemical and clinical manifestations of
vitamin B12 deficiency [66,71]. Evidence points out that, out of large doses of cyanocobal-
amin given orally, 1% is absorbed and provides increase in serum B12 levels so that the
daily requirements are covered (for review see [72]). Based on these data, we chose in
our trial to assign a daily oral dose methylcobalamin of 1000 µg/24 h to the active group.
This dose indeed normalized B12 levels and may accordingly be recommended, at least
in patients with (absolute or “relative”) B12 deficiency. We used a new dispersible tablet
preparation with an enhanced bioavailability after being dispersed in the mouth. Sublin-
gual administration has the additional advantages of allowing for vitamin B12 absorption
by sublingual capillaries [67,68], thus being well accepted by patients with swallowing
difficulties and ensuring higher adherence rates.
With respect to our findings, the improvement in SNCV was in accordance with
other studies, both in humans and animals [36,39]. The findings were compatible with the
reported action of methylcobalamin on the synthesis and regeneration of myelin [73,74], as
well as enhanced nerve conduction and decreased neurotransmitter levels [74].
More importantly, we found that B12 supplementation resulted in improvements
of somatosensory symptoms such as pain and paresthesia. Though our patients did not
present with extremely painful neuropathy (mean pain score about 19 out of 38) [53], the
pain level in the present study significantly decreased by 7%. Similar effects could be shown
in our previous study [51] and other studies [3,33,63,75]. These findings once again confirm
the analgesic action of B12 [63,73], possibly mediated by an increase of the availability and
effectiveness of noradrenaline and 5-hydroxytryptamine [76] in the descending inhibitory
pain modulation system (endogenous opioid system).
Unexpectedly, the active treatment group did not show a significant improvement
in CARTs. However, the placebo group showed a trend towards the deterioration of
CARTS, suggesting a potential favorable effect of B12 on DAN despite the absence of
a statistically significant result. This aspect is corroborated by a few studies that have
suggested a beneficial effect of methylcobalamin on autonomic symptoms and specifically
on CAN [7,35]. Whether the beneficial effect is exerted mainly in the parasympathetic [7]
or sympathetic [77] nervous systems remains unknown. A particular way to estimate
autonomic (dys)function is to measure sudomotor function by SUDOSCAN, a point-of-care
device. Sudomotor function depends not only on the sympathetic cholinergic system but
also on somatic innervation. Therefore, SUDOSCAN may be used as a simple method to
screen and monitor the progression of peripheral nerve and cardiac sympathetic dysfunc-
tion in the context of a busy diabetes clinic [78]. SUDOSCAN provides excellent sensitivity
and good specificity for DPN, as well as moderate sensitivity for CAN. Of particular im-
portance is that ESCF is considered to be a more sensitive marker for detecting neuropathy
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compared to ESCH [44,79–82]. ESCF readings are closely related to nerve conduction
scores [47,78,83]. Altogether, these data argue that SUDOSCAN may be a reliable and early
detector of small fiber neuropathy [78], in addition to DPN and sudomotor dysfunction,
all of which are critical factors for the development of the “diabetic foot.” It is of note that
sudomotor dysfunction in DM patients is often underestimated and therefore remains
undiagnosed in clinical practice [49]. In the present study, both ESCH and ESCF signifi-
cantly improved in the active group, indicating a favorable effect of B12 supplementation
in helping to prevent “diabetic foot,” at least in the specific group of diabetic patients.
However, this potential benefit will need to be confirmed in other well-designed and large
prospective studies [44,78,80,81,84–86].
There were no adverse events of the administration of B12, as other studies have also
shown [3,33,34,51,61].
Our study had certain limitations. All participants were followed in a single diabetes
center and were Caucasian. This ensured the homogeneity of the sample population but
did not allow for the extrapolation of the results to other populations. We did not measure
glutamic acid decarboxylase, intrinsic factor, or parietal cells autoantibodies because our
population had confirmed DM2 and we had excluded patients with pernicious anemia.
In addition, we only measured the functionality of sural nerve and not of nerves in arms
and hands. Sural nerve function assessment is widely accepted to represent the respective
function of other nerves too. We also did not measure homocysteine and methylmalonic
acid, because they are often not available in the daily practice of the diabetes clinic, have
high costs, and are not necessarily needed for the diagnosis of vitamin B12 deficiency.
In summary, this study showed that the increase of B12 levels with an oral dispersible
tablet containing 1000 µg methylcobalamin for 12 months in patients with DN improved
the patients’ neurophysiological parameters, sudomotor function, pain score, and QoL.
Future studies will need to address still open questions, such as whether in the absence
of B12 deficiency supplementation with the vitamin has any effects on established DN,
whether B12 administration has favorable effects on the prevention of DN or the preven-
tion of deterioration of subclinical DN, and which forms of DN are mostly improved by
B12 supplementation.
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Appendix A
Table A1. Blood pressure and lipid profile at baseline and end of follow-up for both groups.
Active Placebo
p c
Baseline 12 Months p a Baseline 12 Months p b
Systolic BP 132.2 ± 17.5 135.8 ± 19.9 0.530 138.9 ± 17.5 136.7 ± 19.8 0.256 0.547
Diastolic BP 83.8 ± 9.2 81.5 ± 8.7 0.540 85.7.1 ± 9.2 8.5 ± 8.9 0.560 0.350
Total Cholesterol 176.4 ± 42.4 169.64 ± 41.3 0.535 173.5 ± 51.3 175.6 ± 51.7 0.635 0.905
Triglycerides 102.6 ± 77.97 107.6 ± 69.6 0,851 110.3 ± 73.3 105.9 ± 72.3 0.075 0.998
HDL Cholesterol 52.3 ± 16.5 49.8 ± 15.9 0.381 49.6 ± 12.3 46.3 ± 12.5 0.235 0.336
LDL Cholesterol 104.1 ± 47.2 102.6 ± 45.8 0.585 99.5 ± 45.6 93.5 ± 52.1 0.658 0.778
a For difference during follow-up in the active group; b for difference during follow-up in the placebo group; c for difference between
groups. Abbreviations: BP: blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein.
Table A2. Other laboratory markers at baseline.
Active Placebo p
Hematocrit (%) 39.4 ± 2.4 40.4 ± 3.3 0.143
Thyroid Stimulating Hormone (µIU/mL) 2.32 ± 1.1 3.5 ± 5.9 0.286
Aspartate Aminotransferase (U/L) 19.8 ± 9.1 19.4 ± 9.3 0.172
Alanine Transaminase (U/L) 19.2 ± 7.4 24.1 ± 14.8 0.089
Urea (mg/dL) 36.2 ± 6.1 34.4 ± 7.5 0.260
e-GFR (mL/min/1.73 m2) * 80.5 ± 2.5 81.3 ± 2.1 0.987
* e-GFR was calculated by the CKD-EPI formula. Abbreviations: eGFR: estimated glomerular filtration rate.
Table A3. Reference intervals for biochemical markers shown in Table 2.
Reference Values
HbA1c (%) 4–6%
HbA1c (mmol/L) <42 mmol/L
Vitamin B12 (pmol/L) 145–569 pmol/L




Mean Corposcular Volume (fL) 80.0–99.0 fL
Platelets (103/µL) 150–450 103/µL
Folic Acid (nmol/L) 8.83–60.8 nmol/L
Creatinine (mg/dL) 0.50–1.20 mg/dL
Cholesterol (mg/dL) 100–200 mg/dL
Triglycerides (mg/dL) 50–200 mg/dL
High Density Lipoprotein (mg/dL) 45–90 mg/dL
Low Density Lipoprotein (mg/dL) <130 mg/dL
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